Regulatory Landscape Newsletter – October 2024

This is our Regulatory Landscape newsletter for October 2024 with our monthly insights on the evolving market for Regulatory professionals.    For the month of September there were approximately 87 new Regulatory positions posted at smaller biopharma companies in the US. This is down 5% from August but up 30% from September 2023.  56% of these[…]

Regulatory Salary Expectations in 2024

Based on our March 2024 survey, over 51% of Regulatory Affairs professionals are considering changing jobs this year. The ability to work remotely and higher compensation and benefits are the biggest driving factors in seeking a new position. In order to understand senior Regulatory candidates’ salary expectations in 2024, Dennis Partners once again surveyed the[…]

Regulatory Landscape Newsletter – September 2023

This is our Regulatory Landscape newsletter for September 2023 with our monthly insights on the evolving market for Regulatory professionals.    For the month of August there were about 80 new Regulatory positions posted at smaller biotech and pharma companies in the US. This is up about 14% from last month and very similar to the[…]

Pay Transparency is Coming: What Employers Should Consider Doing

Pay transparency is coming to the biopharma industry. In fact, there’s already some form of law in place in California, Colorado, Connecticut, Maryland, and Washington with new transparency laws enacting in New York on November 1, 2022.  Job boards such as Indeed are seeing an increase in companies sharing salary ranges.  LinkedIn’s latest Workforce Confidence[…]

Hiring Top Candidates in Today’s Competitive Market

In today’s market, it’s incredibly challenging to find the desired Regulatory talent for growing bio/pharma organizations.  We’ve seen companies adjust levels, rapidly promote people, and lower their expectations.  It’s an arduous process but once you finally are ready to make an offer, it’s becoming increasingly difficult to get the acceptance.  The biggest challenge is that[…]

Regulatory Landscape Newsletter – August 2020

This is our Regulatory Landscape newsletter for August 2020 with our monthly insights on the evolving market for regulatory professionals.  Regulatory hiring remained strong for the month of July with over 100 new regulatory positions posted across the country.  Most of these positions were in clinical regulatory strategy and regulatory CMC along with several new[…]

COVID-19 Update: Observations from a Regulatory Recruiter

The COVID-19 outbreak is affecting both individuals and businesses in a variety of ways.  As a Regulatory Recruiter for the biopharma industry, I speak with both hiring authorities and regulatory professionals every day, and I wanted to share some insights on what I have been hearing over the past week. Some biopharma companies are moving[…]

Top Regulatory News Stories – Week Ending September 27, 2019

Bavarian Nordic announces U.S. FDA approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine) for prevention of Smallpox and Monkeypox disease in adults.  https://www.globenewswire.com/news-release/2019/09/24/1920224/0/en/Bavarian-Nordic-Announces-U-S-FDA-Approval-of-JYNNEOS-Smallpox-and-Monkeypox-Vaccine-Live-Non-replicating-for-Prevention-of-Smallpox-and-Monkeypox-Disease-in-Adults.html Novo Nordisk’s Rybelsus, an oral-semaglutide for type 2 diabetes snagged approval from the U.S. FDA, marking it as the first such treatment to be approved in pill form.    https://www.biospace.com/article/novo-nordisk-snags-fda-approval-for-oral-type-2-diabetes-drug/ Johnson & Johnson’s multiple[…]

Top Regulatory News Stories – Week Ending September 20, 2019

Ardelyx, Inc. announced that the U.S. Food and Drug Administration has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.  https://www.prnewswire.com/news-releases/ardelyx-receives-fda-approval-for-ibsrela-tenapanor-an-nhe3-sodium-transport-inhibitor-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-300917407.html Amplyx Pharmaceuticals announced that the FDA has granted Fast Track designations for both the intravenous (IV) and oral formulations of the[…]

Top Regulatory News Stories – Week Ending September 13, 2019

Five years after securing its first approval in idiopathic lung fibrosis,  Boehringer Ingelheim’s drug Ofev has been cleared to slow the rate of pulmonary decline in patients with another lung scarring disease. https://endpts.com/boehringer-ingelheims-ofev-wins-fda-approval-for-use-in-scleroderma-patients/ Ridgeback Biotherapeutics announced that the Food and Drug Administration has recently granted mAb114, an experimental treatment for Ebola, Breakthrough Therapy designation. https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mab114-300913398.html[…]